Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 11;16(Supplement_2):ii42-ii53.
doi: 10.1093/ecco-jcc/jjac038.

IL-23 Monoclonal Antibodies for IBD: So Many, So Different?

Benjamin D McDonald  1 , Emma C Dyer  1 , David T Rubin  1
Affiliations
Review

IL-23 Monoclonal Antibodies for IBD: So Many, So Different?

Benjamin D McDonald et al. J Crohns Colitis. .

Abstract

Interleukin [IL]-23 is a member of the IL-12 family of cytokines and has been implicated in multiple inflammatory disorders including psoriasis, psoriatic arthritis, and the inflammatory bowel diseases [IBDs]. Blockade of both IL-12 and IL-23 using an antibody that targets a shared subunit is highly effective in treating psoriasis, and recent data suggest similar efficacy in IBD with minimal adverse events. In this review, we summarise published data on the efficacy of anti-IL-12/23 therapies in IBD as well as emerging data on more selective anti-IL-23 specific therapies. Last, we discuss novel therapeutics under development which target the IL-23 pathway in unique ways and suggest that a biomarker-driven approach will soon guide clinicians to prescribe anti-IL-23 therapies to the patients most likely to respond to them.

Keywords: IL-23; Inflammatory bowel disease; monoclonal antibody.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Molecular targets of anti-IL-23 therapies. First generation [blue box], second generation [green box], and third generation [brown box] anti-IL-23 therapies are displayed. Created with biorender.com.
See this image and copyright information in PMC

References

    1. Tait Wojno ED, Hunter CA, Stumhofer JS. The immunobiology of the interleukin-12 family: room for discovery. Immunity 2019;50:851–70. - PMC - PubMed
    1. Vignali DAA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012;13:722–8. - PMC - PubMed
    1. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699–708. - PubMed
    1. Thierfelder WE, van Deursen JM, Yamamoto K, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996;382:171–4. - PubMed
    1. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950–7. - PubMed

Grants and funding